ReviewCellular & molecular immunology2018
The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.
Review in Cellular & molecular immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 127 citations in OpenAlex.
- Roles of V-domain Ig suppressor of T-cell activation-mediated immunoregulation in tumor immune escape (Review).Oncology letters · 2026Review
- Single-cell atlas of the mouse ovary reveals molecular drivers of aging and senescence during the estropausal transition.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Expression of VISTA on peripheral blood mononuclear cells in Systemic lupus erythematosus: association with disease activity and treatment status.Clinical and experimental medicine · 2026Article
- T cell-intrinsic VISTA expression promotes resistance to CTLA-4 blockade by restricting CD8+ T cell responses.The Journal of clinical investigation · 2026Article
- Machine learning-guided discovery and molecular dynamics simulation of VISTA-targeted immunotherapeutics for cancer immunotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- CRISPR/Cas9 Technology for Modifying Immune Checkpoint in CAR-T Cell Therapy for Hematopoietic Malignancies.Current gene therapy · 2026Review
- Targeting VISTA as a novel immunotherapy for skin cancer.Frontiers in immunology · 2026Review
- VISTA expressed on tumor cells is regulated by m6A and influences immune microenvironment through STAT3/CCL22 in NSCLC.Journal of translational medicine · 2025Article
- Dual membrane receptor degradation via folate receptor targeting chimera.Nature communications · 2025Article
- Emerging new immune checkpoint inhibitors in solid tumor immunotherapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.British journal of cancer · 2025Article
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- The relevance of B7-H3 and tumor-associated macrophages in the tumor immune microenvironment of solid tumors: recent advances.American journal of translational research · 2025Review
- Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Frontiers in immunology · 2025Review
- Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy.Frontiers in immunology · 2025Article
- MR molecular imaging for monitoring and predicting tumor responses to immunotherapy.Theranostics · 2025Article
- A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma.iScience · 2024Article
- Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment.Heliyon · 2024Review
- Clinical landscape of macrophage-reprogramming cancer immunotherapies.British journal of cancer · 2024Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Among various immunoregulatory molecules, the B7 family of immune-checkpoint receptors consists of highly valuable targets for cancer immunotherapy. Antibodies targeting two B7 family co-inhibitory receptors, CTLA-4 and PD-1, have elicited long-term clinical outcomes in previously refractory cancer types and are considered a breakthrough in cancer therapy. Despite the success, the relatively low response rate (20-30%) warrants efforts to identify and overcome additional immune-suppressive pathways. Among the expanding list of T cell inhibitory regulators, V domain immunoglobulin suppressor of T cell activation (VISTA) is a unique B7 family checkpoint that regulates a broad spectrum of immune responses. Here, we summarize recent advances that highlight the structure, expression, and multi-faceted immunomodulatory mechanisms of VISTA in the context of autoimmunity, inflammation, and anti-tumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.